Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;128(2):354–362. doi: 10.1038/s41416-022-02036-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature Limited 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 3 — Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) before and after treatment with the VEGF inhibitor without and with dietary sodium restriction (DSR). Visits: 1: baseline; 2: end of treatment cycle 1; 3: baseline treatment cycle with dietary sodium restriction; 4: end treatment cycle with DSE. In purple, mean BP values. Patients 14 and 16 received amlodipine during the first treatment cycle because of a rise in SBP > 170 mmHg, which could be discontinued during DSR. Patients 1, 4, 11 and 15 received amlodipine or doxazosin during the first treatment cycle and continued during second treatment cycle.